Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)

NCT05180695 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT05180695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05180695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)
Lead sponsor
Centre Leon Berard
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 15, 2022
Completion date
February 28, 2027
Enrollment
47 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced soft-tissue sarcoma, metastatic soft-tissue sarcoma